Immunic CEO Dr Daniel Vitt provides hope for sufferers during Celiac Awareness Month
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt joins Proactive's Stephen Gunnion with more on the serious and lifelong nature of celiac disease to mark Celiac...
Stay updated with breaking news from Daniel Vitt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt joins Proactive's Stephen Gunnion with more on the serious and lifelong nature of celiac disease to mark Celiac...
Immunic Inc CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion with news of the publication of extended data from the Phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting...
NEW YORK, April 4, 2024 /PRNewswire/ -- Immunic, Inc. , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and...
Immunic Inc (NASDAQ:IMUX) announced that it will present data from its Phase 2 CALLIPER and CALVID-1 clinical trials of its lead asset vidofludimus calcium...
The Dow Jones index closed lower by over 20 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.